0A4U
:LSE

Add to watchlist
CA$8.60
Last updated:11/08/2021
0A4U: LSE
CA$8.60
BELLUS Health Inc.

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquarter…

P/E ratio
-
vs. 0.00x forward
Stock volatility (Beta)
past 12 months
Become our supporter to unlock all data!
Company profile
CEO
Not defined
Website
Market capitalization
Not defined